Non-Hodgkin Lymphoma
Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 43 A phase 1a/1b dose escalation trial of single agent TTl-621, a novel biologic targeting CD47, in subjects with relapsed of refractory hematologic malignancies. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 52 A Phase 1 Dose Escalation Study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of ARQ 531 in selected subjects with Relapsed or Refractory Hematologic Malignancies. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 56 TTI-622-01 A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 59 A phase 1a/1b open label, multicenter study evaluating the safety and pharmacokinetics of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed of refractory B-Cell Non Hodgkin Lymphoma. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
HR 62 A Phase 1/2 Open-Label, Clinical Trial of TC-110 T Cells in adults with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 140 A Single Arm, Open label, multi-center Phase I/II study evaluating the safety and clinical activity of AUTO3, a CAR-T Cell treatment targeting CD19 and CD22 and consolidation with Anti-PD1 Antibody in patients with relapsed of refractory Diffuse Large B Cell Lymphoma. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 147 Tisagenlecleucel versus standard of care in adult patients with relapsed of refractory aggressive B-CELL Non-Hodgkin Lymphoma. A randomized, open label phase lll trial (BELINDA). |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 151 A Single-Arm, open –label phase ½ study evaluating the safety and efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR-T Cell Therapy in patients with relapsed/refractory Large B-Cell and Follicular Lymphoma. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 155 Single Arm, Phase ll Study of Acalabrutinib as Post-Autologous Blood or Marrow transplant (BMT) maintenance therapy in subjects with Mantel Cell Lymphoma. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 166 Safety and efficacy of GEN3009 (DuoHexaBody-CD37) in relapsed or refractory B-cell Non-Hodgkin Lymphoma – A first in human, Open label, Phase 1/lla dose escalation trial with dose expansion cohorts. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 168 A Single-Arm, Open-Label, Phase 1/2 study evaluating the safety, efficacy and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR-T Cell Therapy in subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL) |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 171 A Phase 1/2, open label, dose escalation trial of GEN3013 in patients with relapsed, progressive or refractory B Cell Lymphoma. |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 172 A Phase 3, randomized, double – blind, placebo controlled, multicenter study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) alone versus in combination with Acalabrutinib in subjects <65 years with previously untreated non-germinal center Diffuse Large B Cell Lymphoma. |